<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Template%3ACrofab_indications</id>
	<title>Template:Crofab indications - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Template%3ACrofab_indications"/>
	<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Template:Crofab_indications&amp;action=history"/>
	<updated>2026-05-13T12:29:26Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.38.2</generator>
	<entry>
		<id>https://wikem.org/w/index.php?title=Template:Crofab_indications&amp;diff=50148&amp;oldid=prev</id>
		<title>Jonas: Created page with &quot;The following criteria for administration after Crotalidae bite allows for clinician judgment and shared decision making with the patient due to the extreme cost of Crofab&lt;ref...&quot;</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Template:Crofab_indications&amp;diff=50148&amp;oldid=prev"/>
		<updated>2016-01-01T16:43:13Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;The following criteria for administration after Crotalidae bite allows for clinician judgment and shared decision making with the patient due to the extreme cost of Crofab&amp;lt;ref...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;The following criteria for administration after Crotalidae bite allows for clinician judgment and shared decision making with the patient due to the extreme cost of Crofab&amp;lt;ref&amp;gt;Lavonas EJ et al: Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med. 2011; 11.&amp;lt;/ref&amp;gt; &lt;br /&gt;
#Progression of swelling&lt;br /&gt;
#Abnormal results on lab tests (plt &amp;lt; 100,000 or fibrinogen &amp;lt; 100)&lt;br /&gt;
#Systemic manifestations (unstable vitals or AMS)&lt;br /&gt;
#Neuromuscular toxicity&lt;br /&gt;
No studies show reduction in mortality from antivenom administration.&lt;/div&gt;</summary>
		<author><name>Jonas</name></author>
	</entry>
</feed>